220 related articles for article (PubMed ID: 35790987)
1. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.
Lin J; Guo Q; Guo Z; Lu T; Chen G; Lin S; Chen M; Chen C; Lu J; Zong J; Tang L; Chen Y; Pan J
Radiat Oncol; 2022 Jul; 17(1):117. PubMed ID: 35790987
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy and checkpoint inhibitor for locally recurrent unresectable nasopharyngeal carcinoma.
Wu JS; Jen CW; Chen HH; Cheng SH
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34253513
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
4. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma.
Ozyigit G; Cengiz M; Yazici G; Yildiz F; Gurkaynak M; Zorlu F; Yildiz D; Hosal S; Gullu I; Akyol F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e263-8. PubMed ID: 21514737
[TBL] [Abstract][Full Text] [Related]
8. A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
Li L; Chen L; Fan M; Tian Y; Ai H; Yan L; Li F; Lan M; Lai X; Huang Y; Xu P; Feng M; Lang J
Oral Oncol; 2024 Mar; 150():106695. PubMed ID: 38262250
[TBL] [Abstract][Full Text] [Related]
9. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
10. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
11. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
12. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric comparison between RapidArc and HyperArc techniques in salvage stereotactic body radiation therapy for recurrent nasopharyngeal carcinoma.
Ho HW; Lee SP; Lin HM; Chen HY; Huang CC; Wang SC; Yang CC; Lin YW
Radiat Oncol; 2020 Jul; 15(1):164. PubMed ID: 32641082
[TBL] [Abstract][Full Text] [Related]
14. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
Zhou X; Niu X; Liu P; Ou D; Zhu Y; Wang X
Front Immunol; 2021; 12():762663. PubMed ID: 34777379
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.
Yeo ELL; Li YQ; Soo KC; Wee JTS; Chua MLK
Chin Clin Oncol; 2018 Apr; 7(2):15. PubMed ID: 29764160
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma.
Yang J; Liao W; Su S; Zeng N; Zhang S; He J; Chen N
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38148586
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
19. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
Ding X; Zhang WJ; You R; Zou X; Wang ZQ; Ouyang YF; Peng L; Liu YP; Duan CY; Yang Q; Lin C; Xie YL; Chen SY; Liu YL; Gu CM; Xie RQ; Huang PY; Hong MH; Hua YJ; Chen MY
J Clin Oncol; 2023 May; 41(14):2571-2582. PubMed ID: 36735896
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]